Table 3: Follow-up of patients with locally advanced rectal cancer receiving capecitabine/irinotecan +/− cetuximab based chemoradiotherapy as preoperative treatment ().

Capecitabine/irinotecan Capecitabine/irinotecan + cetuximab

Alive2336
Dead 1413
Follow-up (months); median (range)105.5 (1.3–133.7)71.9 (7–103.3)